NCT04871724

Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects

A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Enanta Pharmaceuticals, Inc · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects

Conditions

• RSV Infection

Interventions

Type	Name	Description
DRUG	EDP-938	Subjects will receive EDP-938 once daily on Days 1 and 14
DRUG	Fluconazole	Subjects will receive fluconazole once daily on Days 5 to 18

Timeline

• Start date: 2021-03-12
• Primary completion: 2021-03-30
• Completion: 2021-04-16
• First posted: 2021-05-04
• Last updated: 2021-05-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study